original articlesthoracic tumorsA randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
thoracic tumors
Under an Elsevier user license
open archive
Key words
trametinib
MEK inhibitor
docetaxel
NSCLC
KRAS
progression-free survival
Cited by (0)
- †
This manuscript represents an original clinical trial. Data from this study were reported at the 2013 ASCO, Chicago, IL, USA.
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.